Sight Sciences Inc (NASDAQ:SGHT), a developer of surgical and non-surgical eye care technologies, reported its fourth quarter and full-year 2025 financial results after the market close on March 4, 2026. The company's performance presented a mixed picture, beating analyst expectations on profitability but falling slightly short on revenue, which appears to have driven a negative initial market reaction.
Earnings Performance Versus Estimates
The core of the earnings report shows a divergence between top-line revenue and bottom-line earnings per share (EPS).
- Revenue: For Q4 2025, Sight Sciences reported revenue of $20.39 million. This came in just below the consensus analyst estimate of $20.81 million, representing a slight miss.
- Earnings Per Share (Non-GAAP): The company reported a non-GAAP net loss per share of ($0.08). This figure significantly outperformed the analyst expectation for a loss of ($0.14) per share, indicating better-than-anticipated cost management or operational efficiency during the quarter.
Market Reaction and Recent Performance
The immediate after-hours trading reaction to the earnings release was negative, with the stock declining approximately 4.8%. This suggests investors may have focused more intently on the revenue shortfall than the earnings beat. This reaction extends a challenging short-term trend for the stock, which is down over 16% in the past month. However, it's worth noting the stock had shown slight stability in the very recent period, posting modest gains over the past one and two weeks leading into the report.
Company Outlook and Analyst Expectations
A key component of the announcement was the initiation of financial guidance for the full 2026 fiscal year. While the specific numerical guidance from management was not detailed in the provided context, the press release confirms that it was issued. This forward-looking information is typically weighed against the market's existing expectations.
Analysts, ahead of this report, had already established estimates for Sight Sciences' future performance. Their full-year 2026 consensus calls for sales of approximately $87.1 million. For the upcoming first quarter of 2026, the consensus estimates are for revenue of $19.73 million and a non-GAAP EPS loss of ($0.17). Investors will be scrutinizing the company's provided 2026 guidance to see if it aligns with, exceeds, or falls below these analyst projections, as that comparison often drives longer-term price movement.
Summary of the Announcement
Beyond the raw numbers, the press release from Sight Sciences served to communicate the company's year-end status and future direction. The primary takeaways include the confirmation of financial results for Q4 and full-year 2025, highlighting the company's ongoing commercial efforts for its OMNI Surgical System for glaucoma and its TearCare System for dry eye disease. Most importantly, the company used the occasion to set its financial targets for the coming year, providing investors with a benchmark against which to measure its 2026 progress.
For a detailed history of earnings reports and a complete view of analyst estimates, you can review the data here.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer to buy or sell any security. Investing involves risk, including the potential loss of principal. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
